Low Dose Naltrexone (LDN)
According to the Low Dose Naltrexone home page [LDN], LDN has been seen to benefit
dermatomyositis, which is considered to be an autoimmune disease.
[LDN] reports that all patients with autoimmune processes whom the late
Dr. Bihari [Bihari2003] treated using LDN "have experienced a halt in progression of
their illness. In many patients there was a marked remission in signs and symptoms of the
disease." Dr. Bihari suggests a 50% to 70% overall response rate [Bihari2003].
[Tran2018 🕮 ] reports a case of successful treatment of dermatomyositis with low-dose naltrexone.
Dr. Weyrich has been trained to use Low Dose Naltrexone (LDN).
However, Dr. Weyrich has not treated any cases of Dermatomyositis with LDN.
Please see What is Low Dose Naltrexone?
for more information.
Immune System Balancing
[McCulley2018, pg 28] reports that dermatomyositis is a localized
autoimmune disorder, and proposes an approach to treating this disease, which should be
supervised by a properly trained medical professional.
Dr. Weyrich has considerable interest in this topic, but has
not treated any cases of dermatomyositis
with Immune System Balancing.
Please see What is Immune System Balancing?
for more information.
Neurotransmitter Balancing
Neuro Research [Hinz2015] reports that chronic diseases such as Dermatomyositis
can be benefited by balancing neurotransmitter levels in the body.
Dr. Weyrich has been trained in neurotransmitter balancing protocols, but has not treated
chronic diseases such as Dermatomyositis using this technique.
Please see What is Neurotransmitter Balancing?
for more information.